Squamous Cell Carcinoma PBMC

Squamous Cell Carcinoma PBMC

Squamous Cell Carcinoma PBMC is collected from IRB-consented donors diagnosed with clinically confirmed Squamous Cell Carcinoma (SCC). These peripheral blood mononuclear cell (PBMC) samples are ideal for analyzing peripheral immune exhaustion and tumor-specific cell subsets. PBMCs are ideal for evaluating immune checkpoint expression, T cell dysfunction, and cellular response to squamous epithelial tumors.

Product Features

  • Cryopreserved, clinically verified SCC PBMC samples
  • Cryopreserved to ensure stability and long-term storage
  • Research Use Only (RUO)

De-identified Donor Data

  • Clinically confirmed SCC diagnosis
  • Donor demographics: age, sex assigned at birth, ethnicity
  • Medical and treatment history available when applicable

Applications

  • Analyzing peripheral immune exhaustion and tumor-specific cell subsets
  • Biomarker discovery and validation
  • Transcriptomic, proteomic, or functional studies
  • Custom assay development and disease modeling

Compliance and Quality

  • IRB-approved collection and electronic informed consent
  • HIPAA-compliant donor data handling

Ordering and Customization

Squamous Cell Carcinoma PBMC is available in standard and custom volumes. Contact learnmore@sanguinebio.com for international requests or documentation needs.

Protocols & Documentation

  • PBMC Isolation from Whole Blood

    Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.

    Download
  • Immune Cell Isolation

    Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.

    Download
  • Choosing the Right PBMC Configuration

    Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.

    Download
  • Thawing Cryopreserved PBMC

    Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.

    Download
  • Informed Consent Form (ICF)

    Available upon request — confirms donor consent for research use and downstream commercialization.

PBMC

Frequently Asked Questions

Showing 1–12 of 30 results

Are samples IRB approved?

1 Answer

YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.

YES – with the exception of GMP leukopaks, all our products are research use only (RUO).

Our complete catalog can be found here: https://sanguinebio.com/products/

Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.

Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.

Sanguine offers flexible prospective colleciton services to tailored to fit your research. For more information and request a quote, please see: https://sanguinebio.com/prospective-biospecimen-collection-services/

Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.

YES – we have in-stock inventory which can be found here https://sanguinebio.com/products/?pro_inventory=inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.

Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.

YES – Unique donors can be specified and guaranteed based on your requirements.

For information about sample quality, please see: https://sanguinebio.com/quality-and-compliance/

YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.

1 2 3
×

Ask a Question

Need a custom PBMC cohort?

Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.

More Information